A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Stopped early · Phase 2

Conditions studied: Triple Negative Breast Cancer, Hepatocellular Carcinoma

In brief

This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.

Key facts

Study ID
NCT03318562
Run by
Effector Therapeutics
People needed
3
Starts
2017-11-21
Expected to finish
2019-01-22
Last updated by the study team
2019-07-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.